Abbott Laboratories (ABT) Capital Expenditures (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Capital Expenditures data on file, last reported at $399.0 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures fell 17.56% year-over-year to $399.0 million; the trailing twelve-month figure through Mar 2026 stood at $2.1 billion (down 9.03% YoY), and the FY2025 full-year result was $2.2 billion, down 1.63% from the prior year.
• Capital Expenditures eased to $399.0 million in Q1 2026, from $689.0 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $755.0 million in Q4 2023 to a low of $321.0 million in Q1 2022.
• A 5-year average of $515.1 million and a median of $502.0 million in 2025 frame the typical range for Capital Expenditures.
• Across the five-year window, Capital Expenditures fell 19.14% in 2022 and surged 33.77% in 2023, its largest moves.
• Tracing ABT's Capital Expenditures over 5 years: stood at $610.0 million in 2022, then increased by 23.77% to $755.0 million in 2023, then declined by 4.64% to $720.0 million in 2024, then decreased by 4.31% to $689.0 million in 2025, then tumbled by 42.09% to $399.0 million in 2026.
• Business Quant data shows ABT's Capital Expenditures at $399.0 million in Q1 2026, $689.0 million in Q4 2025, and $496.0 million in Q3 2025.